Antoinette R. Tan

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Sylvia Adams, P. Schmid, H. S. Rugo et al. · Annals of Oncology · 2018 · 756 citations · Full text

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Sylvia Adams, Sherene Loi, Deborah Toppmeyer et al. · Annals of Oncology · 2018 · 608 citations

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Harold J. Burstein, Yan Sun, Luc Dirix et al. · Journal of Clinical Oncology · 2010 · 523 citations · Full text

Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

John C. Morris, Antoinette R. Tan, Thomas Olencki et al. · PLoS ONE · 2014 · 474 citations · Full text

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 463 citations · Full text

First-line Therapy, Breast Oncology, Medicine +7